Soluble molecules from SS patient plasma modulate Gran-MV plasmin generation capacity in SS. (A) Granulocytes (Gran) were purified from healthy individuals and then incubated with complete or MV-depleted plasma (PFP or MVFP) from SS patients with low (L-SS) or high (H-SS) plasmin capacity. Then, “Gran-induced MVs” (Gran-iMVs) were purified by ultracentrifugation and quantified by flow cytometry, and plasmin generation capacity was measured. (B) MV-PGC of Gran-iMVs (4 × 10⁵) after stimulation with PFP from selected SS patients with low (<1.5 A_405nm × 10⁻³/min, n = 11, L) (blue) or high (>5 A_405nm × 10⁻³/min, n = 10, H) (red). (C) MV-PGC of Gran-iMVs (4 × 10⁵) after stimulation with MVFP from selected SS patients with low (<1.5 A_405nm × 10⁻³/min, n = 11, L) (blue) or high (>5 A_405nm × 10⁻³/min, n = 10, H) (red). (D) MV-PGC of Gran-iMVs (4 × 10⁵) after stimulation with MV-depleted plasma from SS plasma treated with a human neutrophil elastase (NE) blocking antibody or isotype control (n = 11). (E) MV-PGC of Gran-iMVs (4 × 10⁵) after stimulation with MV-depleted plasma enriched with NE (at a concentration range of 0.008-0.3 nM), from selected L-SS patient MV-PGC values (n = 11). Data are mean ± SEM. (F) PGC of MVs extract with CD15 immunomagnetic beads (IMS-MV-PGC) from LPS-treated blood spiked with a range of NE concentrations (0.008-0.3 nM; n = 4). Data are mean ± SEM. (G) Effect of a range of NE concentrations (0.008-0.3 nM) on the uPA/PAI-1 complex (95 kDa and 110 kDa) by zymography (n = 3; lytic zone in percent, image digitally inverted). Data are mean ± SEM. (H) Effect of a range of NE concentrations (0.008-0.3 nM) in the presence of PAI-1 (440 ng/mL) on the MV-PGC of purified Gran-MVs (2 × 10⁶; n = 6). Data are mean ± SEM. *P < .05; **P < .01.